Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (351-360 of 394) with videos related to

Pageof 40
Sort By:
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 20, 2024
Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting ProceedingsCarly Grant, Lourdes Perez-Chada, Rebecca H Haberman, et al.
The Journal of Investigative Dermatology|June 1, 2025
Eosinophilic Fasciitis and Morphea Share Gene Signatures of Inflammatory Cell Death, Self-DNA Recognition, and Enhanced Jak/Signal Transducer and Activator of Transcription SignalingWilliam J Crisler, Rachael Rowley, Oluwadamilola Oke, et al.
JAMA Dermatology|January 24, 2024
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic ReviewLourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, et al.
Rheumatology (Oxford, England)|March 16, 2026
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studiesLaure Gossec, Laura C Coates, Robert B M Landewé, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Rheumatology (Oxford, England)|September 1, 2020
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritisLaura C Coates, Joseph F Merola, Philip J Mease, et al.
The British Journal of Dermatology|August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD studyJoseph F Merola, Albert S Chiou, Emmanuel During, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
JAMA Dermatology|April 29, 2026
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A ReviewSamip Sheth, Joseph F Merola, Brittany N Weber, et al.
Pageof 40

Showing results (351-360 of 394) with videos related to

Sort By:
Pageof 40
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 20, 2024
Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting ProceedingsCarly Grant, Lourdes Perez-Chada, Rebecca H Haberman, et al.
The Journal of Investigative Dermatology|June 1, 2025
Eosinophilic Fasciitis and Morphea Share Gene Signatures of Inflammatory Cell Death, Self-DNA Recognition, and Enhanced Jak/Signal Transducer and Activator of Transcription SignalingWilliam J Crisler, Rachael Rowley, Oluwadamilola Oke, et al.
JAMA Dermatology|January 24, 2024
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic ReviewLourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, et al.
Rheumatology (Oxford, England)|March 16, 2026
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studiesLaure Gossec, Laura C Coates, Robert B M Landewé, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Rheumatology (Oxford, England)|September 1, 2020
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritisLaura C Coates, Joseph F Merola, Philip J Mease, et al.
The British Journal of Dermatology|August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD studyJoseph F Merola, Albert S Chiou, Emmanuel During, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
JAMA Dermatology|April 29, 2026
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A ReviewSamip Sheth, Joseph F Merola, Brittany N Weber, et al.
Pageof 40